|
- Telitacicept - Wikipedia
Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG)
- Telitacicept: First Approval - PubMed
Telitacicept (Tai'ai<sup>®< sup>) is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG)
- Telitacicept: What is it and is it FDA approved? - Drugs. com
Telitacicept is an investigational novel recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor fusion protein that operates by targeting and neutralizing B lymphocyte stimulator (BLyS) and a proliferating-inducing ligand (APRIL) evaluating its use for autoimmune diseases such as rheumatoid arthritis and
- Definition of telitacicept - NCI Drug Dictionary - NCI
A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) fused to a human immunoglobulin (Ig) fragment crystallizable (Fc) domain, with potential immunomodulating activity
- Efficacy and safety of telitacicept in patients with SLE: Results from . . .
Treatment with telitacicept (160 mg weekly) demonstrated favorable clinical outcomes and an acceptable safety profile in patients with moderate to severe SLE Telitacicept obtained its first approval in China in 2021 for the treatment of patients with active SLE
- Science News: Clinical Trial Finds Telitacicept Reduces MG Symptoms . . .
Telitacicept is a recombinant Human Beta lymphocyte stimulating factor receptor fusion protein It comprises the B-cell stimulating factor receptor (Blys), the extracellular soluble part of the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and the Fc part of human IgG1
- Telitacicept – Application in Therapy and Current Clinical Research
Telitacicept is an innovative drug being studied in clinical trials for various autoimmune conditions This article summarizes the current research on Telitacicept’s potential to treat diseases like lupus, IgA nephropathy, and vasculitis by targeting B cells and reducing harmful antibody production
- Telitacicept in patients with active systemic lupus erythematosus . . .
Objectives This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE)
|
|
|